• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 3, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

How not saying ‘cancer’ for low-risk thyroid cancer may affect treatment preferences, patient anxiety

Bioengineer by Bioengineer
August 23, 2018
in Cancer
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Bottom Line: Could removing "cancer" from the terminology for low-risk small papillary thyroid cancers (PTCs) reduce patients' anxiety so they consider less invasive treatment than surgery and avoid possible overtreatment for what can be indolent tumors? An online survey study of 550 Australian men and women without thyroid cancer suggests the answer is "maybe." Total and partial surgical removal of the thyroid are the most common management approaches for patients with PTC, but those procedures come with surgical risk, lifetime medication management and anxiety. In the study, when hypothetical scenarios described PTC as a lesion or abnormal cells, survey respondents were more likely to pick nonsurgical options such as active surveillance and they reported lower levels of anxiety.

Authors: Kirsten McCaffery, Ph.D., the University of Sydney, New South Wales Australia, and coauthors

Related material available on the For The Media website:

— A podcast interview is available for listening and download on this page.

— The commentary, "The Evolving Nomenclature of Thyroid Cancer," by Andrew G. Shuman, M.D., University of Michigan Medical School, Ann Arbor.

To Learn More: The full study is available on the For The Media website.

(doi:10.1001/jamaoto.2018.1272)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Want to embed a link to this study in your story? Link will be live at the embargo time http://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2018.1272

Media Contact

Kirsten McCaffery
kirsten.mccaffery@sydney.edu.au

@JAMAOto

Share12Tweet8Share2ShareShareShare2

Related Posts

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

October 30, 2026
Radiotherapy for oral cavity cancer: mucositis dominates while saliva and gum fluid stay largely stable

Radiotherapy for oral cavity cancer: mucositis dominates while saliva and gum fluid stay largely stable

October 30, 2026

Lung Cancer Pneumonia Risk Models Look Accurate but Almost All Are Flawed

October 30, 2026

Ear seeds ease chemotherapy nerve pain in trial, but only with in-person care

October 30, 2026
Please login to join discussion

POPULAR NEWS

  • Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

    29 shares
    Share 12 Tweet 7
  • Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

    29 shares
    Share 12 Tweet 7
  • ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

    29 shares
    Share 12 Tweet 7
  • Systematic review maps sustainability tensions in offshore wind development

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant

Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast

ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.